The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-19 and is reviewed periodically as new material appears.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
CRF, produced in the PVN, activates CRF1 receptors and CRF2 receptors distributed across limbic circuits. CRF1 receptor activation, which mediates rapid and intense stress responses, triggers acute dynorphin release in limbic stress-responsive regions including the NAcc, basolateral amygdala, dorsal raphe nucleus (DRN), hippocampus, and bed nucleus of the stria terminalis (BNST). CRF2 receptor activation, generally associated with slower, later-phase stress response components, also induces dynorphin-dependent aversive responses such as conditioned place aversion (CPA). Subsequently dynorphin activates KORs expressed on GABAergic and dopaminergic neurons, encoding the aversive and dysphoric qualities of stress exposure. Acutely stress-induced dynorphin release and KOR activation have evolutionarily adaptive functions. KOR-mediated analgesia facilitates physical escape responses to threat, and concurrent KOR-induced dysphoria and aversion promote avoidance and active coping. However, during the delayed temporal phase following acute stress exposure (hours to days), stress-induced KOR signaling initiates intracellular signaling cascades including p38 MAPK and extracellular signal-regulated kinases (ERK) which phosphorylate transcription factors such as cAMP response element-binding protein (CREB) and alter dynorphin and KOR gene expression itself, establishing a self-amplifying cycle.
The WHO funded work in the 1960s at the Dutch National Institute for Public Health and the Environment (RIVM) on growing the Lister/Elstree strain in rabbit kidney cells and tested it in 45,443 Indonesian children in 1973, with comparable results to the same strain of calf lymph vaccine. Two other cell culture vaccines were developed from the Lister strain in the 2000s: Elstree-BN (Bavarian Nordic) and VV Lister CEP (Chicken Embryo Primary, Sanofi Pasteur). Lister/Elstree-RIVM was stockpiled in the Netherlands, and Elstree-BN was sold to some European countries for stockpiles. However, Sanofi dropped its own vaccine after it acquired Acambis in 2008. ACAM2000 is a vaccine developed by Acambis, which was acquired by Sanofi Pasteur in 2008, before selling the smallpox vaccine to Emergent Biosolutions in 2017. Six strains of vaccinia were isolated from 3,000 doses of Dryvax and found to exhibit significant variation in virulence. The strain with the most similar virulence to the overall Dryvax mixture was selected and grown in MRC-5 cells to make the ACAM1000 vaccine. After a successful phase I trial of ACAM1000, the virus was passaged three times in Vero cells to develop ACAM2000, which entered mass production at Baxter. The United States ordered over 200 million doses of ACAM2000 in 1999–2001 for its stockpile, and production is ongoing to replace expired vaccine. ACAM2000 was approved for mpox prevention in the United States in August 2024.
Early in the game, the player is given a research camera; by taking photographs of enemies, the player will cumulatively gain knowledge about the individual foes which translates into attack boosts and other benefits when facing that enemy type in the future. The player collects money by exploring Rapture and from the bodies of defeated foes; this money can be used at vending machines to restock on ammunition, health and EVE, and other items; like security cameras, vending machines can be hacked to reduce the costs of items from it.
==== Other optical imaging ==== For in vivo fluorescence-based optical imaging, dyes that emit near infrared (NIR) wavelengths >700 nm are most effective, such as indocyanine green, but encounter limitations with reduced circulation time and nonspecific interactions with other biological factors that affect the fluorescence. pH-sensitive nanogels with functionalized surface receptors to target cancer cells were loaded with a fluorescent dye that was only released upon endocytosis. These nanogels successfully generated a fluorescent signal from within the cancer cells and many other groups have developed similar technologies.
Sources: en.wikipedia.org
The types of entrees vary with the producer and the issued menu (of which there are usually 7 to 12), but the common set is based on a traditional Russian outdoorsmen fare, is largely formed out of the commercially available canned food, and usually includes 1 portion of stewed beef or pork, two meat-with-vegetables dishes, like various porridges, stews or canned fish, and one or two spreads, such as liver pâté, sausage stuffing or processed cheese. Desserts may include fruit jams, chocolate and/or walnut spreads, chocolate bars, sweetened condensed milk, etc., but baked goods are usually avoided out of concerns about their shelf life. Other variants may add canned speck and/or dried fish or exchange the hexamine tablets for the flameless heater.
Controversy soon arose over the size of UNTAG's military component, as the member states of the Security Council expected to cover the majority of the costs were irritated by its relatively large size. However, Angola, Zambia, and other states sympathetic to PLAN insisted that a larger force was necessary to ensure that South Africa did not interfere with independence proceedings. Against their objections UNTAG's force levels were reduced from the proposed 7,500 to three battalions of 4,650 troops. This slashed projected expenses by nearly 300 million dollars, but the Security Council did not approve the revised budget until 1 March 1989. The inevitable delay in UNTAG's full deployment ensured there were insufficient personnel prepared to monitor the movement of PLAN and the SADF or their confinement to bases on 1 April 1989, when the permanent cessation in hostilities was to take effect. Secretary-General de Cuéllar urged restraint in the interim on both sides to avoid jeopardising the de facto ceasefire maintained since August 1988 or the 1 April implementation schedule. Nevertheless, PLAN took advantage of the political uncertainty in the weeks following the UNTAG budget debate to begin moving its forces in Angola closer to the border. Since the early 1980s PLAN had consistently stated its intention to establish camps inside South West Africa during any future political transition, a notion rejected with equal consistency by the South African government.
==== Distribution ==== The volume of distribution of ramelteon is 73.6 L, which suggests substantial tissue distribution. The plasma protein binding of ramelteon is 82% independently of concentration. Ramelteon is primarily bound to albumin (70%). The medication is not selectively distributed to red blood cells.
=== Pruning === Blackcurrant fruit is borne primarily on one-year-old shoots. Newly planted bushes should be pruned severely, cutting all shoots back to two buds above ground level. This gives the plant a chance to get properly established before needing to put its energy into producing fruit. The general rule when pruning is to remove all weak shoots and those growing out sideways which may get weighed down when fruiting. The remaining branches should be thinned to remove old unproductive wood and to encourage new shoots. An established bush should not be allowed to become overcrowded and should have about one third of its main branches or stems removed each year. When harvesting by machine, plants with an upright growth habit are encouraged.
=== Medical guidelines and recommendations === In 2015, the scientific advisory panel of U.S. Department of Health and Human Services and U.S. Department of Agriculture for the 2015 iteration of the Dietary Guidelines for Americans dropped the previously recommended limit of consumption of dietary cholesterol to 300 mg per day with a new recommendation to "eat as little dietary cholesterol as possible", thereby acknowledging an association between a diet low in cholesterol and reduced risk of cardiovascular disease. A 2013 report by the American Heart Association and the American College of Cardiology recommended focusing on healthy dietary patterns rather than specific cholesterol limits, as they are hard for clinicians and consumers to implement. They recommend the DASH and Mediterranean diet, both of which are low in cholesterol. A 2017 review by the American Heart Association recommends switching saturated fats for polyunsaturated fats to reduce cardiovascular disease risk. Some supplemental guidelines have recommended doses of phytosterols in the order of 1.6–3.0 grams per day (Health Canada, EFSA, ATP III, FDA). A meta-analysis demonstrated a 12% reduction in LDL-cholesterol at a mean dose of 2.1 grams per day. The benefits of a diet supplemented with phytosterols have also been questioned.
Sources: en.wikipedia.org
These latter amino acids are therefore termed "ketogenic" amino acids, whereas those that enter the citric acid cycle as intermediates can only be cataplerotically removed by entering the gluconeogenic pathway via malate which is transported out of the mitochondrion to be converted into cytosolic oxaloacetate and ultimately into glucose. These are the so-called "glucogenic" amino acids. De-aminated alanine, cysteine, glycine, serine, and threonine are converted to pyruvate and can consequently either enter the citric acid cycle as oxaloacetate (an anaplerotic reaction) or as acetyl-CoA to be disposed of as CO2 and water. In fat catabolism, triglycerides are hydrolyzed to break them into fatty acids and glycerol. In the liver the glycerol can be converted into glucose via dihydroxyacetone phosphate and glyceraldehyde-3-phosphate by way of gluconeogenesis. In skeletal muscle, glycerol is used in glycolysis by converting glycerol into glycerol-3-phosphate, then into dihydroxyacetone phosphate (DHAP), then into glyceraldehyde-3-phosphate. In many tissues, especially heart and skeletal muscle tissue, fatty acids are broken down through a process known as beta oxidation, which results in the production of mitochondrial acetyl-CoA, which can be used in the citric acid cycle. Beta oxidation of fatty acids with an odd number of methylene bridges produces propionyl-CoA, which is then converted into succinyl-CoA and fed into the citric acid cycle as an anaplerotic intermediate.
. They are calculated for the Gaussian distribution of asperities, which have been shown to be unrealistic for engineering surface but can be assumed where friction, load carrying capacity or real contact area results are not critical to the analysis.
The program was intended to be leading-edge, and many features of the program which were legal at the time, including Tribulus and intravenous vitamin C, were outlawed by 2014. Most of the supplements were administered away from Essendon's Windy Hill facilities. A total of 38 players consented to the program, although ASADA ultimately pursued cases against only 34 of those players, based on the supporting evidence it found through the investigation. The program of injections began in November 2011. In January 2012, Essendon's club doctor, Dr Bruce Reid, raised concerns about aspects of the program to the club. In particular, Dank had not liaised with Reid on the details of the program, which included administering substances that Reid had not personally approved, which was against the historical chain of accountability within the club. Reid wrote a letter to Hird and club general manager Paul Hamilton in January, recording his opinion that the substances Dank was administering were "playing at the edge" of legality with the potential to "read extremely badly in the press for [the] club", and that he was unconvinced that either the benefits or the side effects were well understood. At that point, the club's administrators agreed that Reid's approval was required in the future; however, evidence gathered during the investigation indicated Reid was largely kept out of the loop from that point on.
Emus flocked to the Chandler and Walgoolan area during a dry spell, damaging rabbit fencing and devastating crops. An attempt to drive them off was mounted, with the army called in to dispatch them with machine guns; the emus largely avoided the hunters. Emus are large, powerful birds, and their legs are among the strongest of any animal and powerful enough to tear down metal fencing. The birds are very defensive of their young, and there have been two documented cases of humans being attacked by emus.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.